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Pemphigus is a serious autoimmune disease characterized by acantholysis (i.e., the loss of the intercellular connections between epidermal cells) and subsequent blistering of the skin and oral mucosa, mediated by autoantibodies directed against intercellular antigens such as desmoglein-3 and desmoglein-1.\[[@ref1]\] There are three immunologic forms of pemphigus, namely, pemphigus foliaceus, pemphigus vulgaris (PV), and paraneoplastic pemphigus. PV, the most common subset of pemphigus diseases, accounts for 70% of the total cases.\[[@ref2]\] The disease is rare with potentially fatal consequences and has a reported incidence of 0.1--0.5 cases per 100,000 individuals worldwide per year.\[[@ref2]\] PV is seen worldwide with a predilection of Mediterranean people and Ashkenazi Jews. It is slightly predominant in women and primarily manifests in adults during the fifth and sixth decades of life.\[[@ref2]\]

Oral mucosa is most often the initial site and, in many cases, the only site of disease penetration. PV is an antibody-mediated disorder characterized by autoantibodies directed against proteins of the desmosome (desmogleins 1 and 3), leading histologically to intraepithelial cleavage and clinically to vesicles and erosions on the epithelium of the mucous membranes and the skin. Oral signs are characterized by erosions or flaccid bullae, which are extremely fragile when subjected to the slightest mechanical irritation.\[[@ref3]\] Any site in the mouth may be involved, but the soft palate and buccal, gingival, and lower-lip mucosae usually predominate. Gingival involvement may manifest as desquamative gingivitis.\[[@ref4]\] Affected oral tissues are highly friable with a tendency to bleed and sheer when subjected to minor trauma. Patients affected by these chronic, painful ulcers often complain of discomfort while eating spicy or sour foods and performing daily oral functions, including routine oral hygiene.\[[@ref4]\] Because development of oral lesions may precede skin lesions, it is not common for a patient having this disease to seek care first from a dentist. The clinical pathognomonic sign of this disease is the Nikolsky\'s sign: gentle lateral pressure applied to an area adjacent to the affected site forms a blister. The definitive diagnosis of PV cannot be based solely on clinical examination, as several other oral vesiculobullous and ulcerative lesions have a similar appearance such as lichen planus, pemphigoid, and erythema multiforme.\[[@ref4][@ref5][@ref6][@ref7]\] An incisional, perilesional biopsy containing intact epithelium is required for a definitive diagnosis. Deposits of autoantibodies are evidenced by direct immunofluorescence. Indirect immunofluorescence and enzyme-linked immunosorbent assay (ELISA) quantify the circulating amount of autoantibodies.\[[@ref5]\] The main treatment consists of administering corticosteroid and immunosuppressive drugs\[[@ref5]\] and in case of resistance, rituximab is the preferred choice. Patients with oral PV require prosthodontic treatment with removable prosthesis. Vesicular-bullous disease may represent a severe complication in the management of patients, for necessary care in handling the oral tissues.\[[@ref8][@ref9][@ref10]\]

Our study aimed to evaluate and describe the possibility of rehabilitating three patients who suffered from oral PV with a removable prosthesis, although the friction of the same prosthesis on soft tissues is one of the causes of the development of bullous lesions which could break, causing oral mucosal pain and erosion.
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Three patients (2 males and 1 female), treated at the Oral Pathology and Medicine Section of the Dental School of the University of Bari, underwent biopsy, direct immunofluorescence \[[Figure 1](#F1){ref-type="fig"}\], and ELISA to confirm the diagnosis of PV\[[@ref11]\] \[[Figure 2](#F2){ref-type="fig"}\]. Age of the three patients at the first presentation was 64, 62, and 60 years; one of them was also affected by lingual Kaposi\'s sarcoma. Initial treatment consisted of oral prednisone (1 mg/kg die), the dosage of which was decreased gradually according to clinical improvement. After the oral lesion\'s remission, during the minimal dosage maintenance phase, we took a primary impression with an irreversible hydrocolloid impression material, by using a complete tray; we used dental plaster to obtain a primary cast, and we realized individual trays using acrylic resin material; after border the molding, we took the final impressions. The baseplates were prepared for the realization of a removable acrylic resin prosthesis in the upper and lower jaws. The patients were treated with total removable upper and lower acrylic prostheses. The treatment of all the three patients took place between February and July 2011. After treatment, they underwent periodic quarterly checks to assess any complications and/or worsening on the diseased oral mucosa of the foreign body represented by the removable prosthesis. The follow-up was 87 months on an average. This study was conducted in accordance to the principles of the Declaration of Helsinki, and all the patients signed an informed consent.

![Direct immunofluorescence test in pemphigus vulgaris: There is evidence of intraepithelial cleavage](JISPCD-9-423-g001){#F1}

![Clinical presentation in one of the patients of the study (there are only oral lesions)](JISPCD-9-423-g002){#F2}
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The typical clinical feature of PV consists in flaccid, thin-walled vesicles and bullae that usually arise on normal skin or mucosa.\[[@ref4]\] The lesions in the oral cavity are superficial and rupture easily, leaving painful, coalesced ulcers with ragged borders. It is difficult for patients to perform adequate oral home care because of pain and discomfort. With early diagnosis and aggressive treatment, between 50% and 80% patients with PV achieve complete remission.\[[@ref12]\]

The medical management of PV involves topical, intralesional, or systemic use of steroids and other immunosuppressive agents. Systemic corticosteroids are the first line of therapy for the treatment of PV. In case of resistance, rituximab is the preferred choice.\[[@ref6]\]

The lack of anomalies in the oral mucosa affected by PV during the 7-year follow-up is reassuring.

Patients with a history of pemphigus must be recalled periodically to examine the prosthesis and the oral mucosa. Some authors suggest to use a prosthesis with soft denture liner with good resilience, color stability, chemical resistance, good bonding to the denture, low water sorption, and resistance to dimensional change.\[[@ref8]\] We paid great attention cutting the acrylic resin dentures, by using rubber wheels on high-speed angle handpieces, as opposed to carbide burs.\[[@ref8]\] It is crucial to obtain a very smooth, highly polished denture, to avoid any mechanical irritation of the mucosa. Careful attention to occlusal harmony and smooth, rounded borders which are molded precisely are vital to successful treatment. Gentle handling of the oral mucosa is necessary so as not to cause further injury. The use of soft liner materials may be recommended as a temporary solution when bullae or other lesions are present.\[[@ref8]\]

Therefore, according to some authors in the literature, wearing tissue-borne removable prosthesis can be difficult with PV lesions; meanwhile, fixed prosthesis is preferred wherever possible and great care should be taken to create optimal gingival contours to prevent inflammation and facilitate hygiene.\[[@ref13][@ref14][@ref15][@ref16]\]

In our opinion, if patients follow rigorous and periodic follow-up as discussed above, along with a corticosteroid immunosuppressive therapy, they may not show any deterioration of their clinical symptoms in wearing removable prosthesis.

Patients with PV should receive regular and frequent dental examinations (every 2--3 months) until extended intervals can be justified. Therefore, the presented patient has been called for follow-up recalls every 3 months.

The most important aspect of PV is its early recognition, diagnosis, and treatment. The dental clinician and health-care team play a critical role in the quality of life for these patients. It is essential to monitor the patient in collaboration with a dermatologist. Although the dental problems in PV can be challenging, a strategic and comprehensive dental planning will have positive outcomes. Patients have tolerated their removable prosthesis well by using it comfortably since the beginning of rehabilitation procedures.

C[ONCLUSIONS]{.smallcaps} {#sec1-4}
=========================

PV typically runs a chronic course, causing blisters, erosions, and ulcers on the mucosa and skin. Oral problems such as blister formation with minimal trauma are usually encountered in patients with PV. Ill-fitting dentures can cause vesiculobullous and ulcerative lesions.

In literature, several researchers revealed that the use of implant-supported prosthesis is the better choice in patients affected by PV.\[[@ref17][@ref18]\] According to the current experience, caution must be exercised about the use of removable prosthesis in these patients. In our experience, if patients follow rigorous and periodic follow-up as discussed above, along with a corticosteroid immunosuppressive therapy, they may not show any deterioration of their clinical symptoms by using removable acrylic resin prosthesis in the upper and lower jaws.

The improvement of the methods of diagnosis and prosthetic treatment of patients with acantholytic pemphigus using removable dentures is promising.
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